COMPANY

Camino Pharma

HQ: San Diego, CA source · caminopharma.com ↗ · West Coast

Keywords: oncology neurology cancer alcohol use disorder depression Smoking Cessation SBP-9330

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Timeline

Jul 20, 2021 Trial start Phase 1: A First-in-Human Study of SBP-9330 in Healthy Subjects source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT04948827	A First-in-Human Study of SBP-9330 in Healthy Subjects	Phase 1	Completed	Jul 20, 2021	Mar 6, 2023 (actual)

Annual award amounts. Total $2.9M.

Jul 30, 2024 NIH award 5U43AA031388-02 FY2024: $994,906 awarded for that fiscal year; activity U43 (SBIR); PI GADIENT, RETO ANDREAS; recipient as written: CAMINO PHARMA, LLC, SAN DIEGO, CA. Preclinical validation of mGlu2 PAMs in source ↗
Sep 20, 2023 NIH award 1U43AA031388-01 FY2023: $973,938 awarded for that fiscal year; activity U43 (SBIR); PI GADIENT, RETO ANDREAS; recipient as written: CAMINO PHARMA, LLC, SAN DIEGO, CA. Preclinical validation of mGlu2 PAMs in source ↗
Jun 24, 2021 NIH award 5R43MH122063-02 FY2021: $449,453 awarded for that fiscal year; activity R43 (SBIR); PI GADIENT, RETO ANDREAS; recipient as written: CAMINO PHARMA, LLC, SAN DIEGO, CA. Negative Allosteric Modulators (NAMs) o source ↗
Jun 5, 2020 NIH award 1R43MH122063-01A1 FY2020: $469,863 awarded for that fiscal year; activity R43 (SBIR); PI GADIENT, RETO ANDREAS; recipient as written: CAMINO PHARMA, LLC, SAN DIEGO, CA. Negative Allosteric Modulators (NAMs) source ↗